Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01926 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Nam H Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computation Biology, Houston, TX. Hauptthemen laut MEDLINE: Li-Fraumeni Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE There exists a barrier between developing and disseminating risk prediction models in clinical settings. We hypothesize that this barrier may be lifted by demonstrating the utility of these models using incomplete data that are collected in real clinical sessions, as compared with the commonly used research cohorts that are meticulously collected. MATERIALS AND METHODS Genetic counselors (GCs) collect family history when patients (ie, probands) come to MD Anderson Cancer Center for risk assessment of Li-Fraumeni syndrome, a genetic disorder characterized by deleterious germline mutations in the TP53 gene. Our clinical counseling-based (CCB) cohort consists of 3,297 individuals across 124 families (522 cases of single primary cancer and 125 cases of multiple primary cancers). We applied our software suite LFSPRO to make risk predictions and assessed performance in discrimination using AUC and in calibration using observed/expected (O/E) ratio. RESULTS For prediction of deleterious TP53 mutations, we achieved an AUC of 0.78 (95% CI, 0.71 to 0.85) and an O/E ratio of 1.66 (95% CI, 1.53 to 1.80). Using the LFSPRO.MPC model to predict the onset of the second cancer, we obtained an AUC of 0.70 (95% CI, 0.58 to 0.82). Using the LFSPRO.CS model to predict the onset of different cancer types as the first primary, we achieved AUCs between 0.70 and 0.83 for sarcoma, breast cancer, or other cancers combined. CONCLUSION We describe a study that fills in the critical gap in knowledge for the utility of risk prediction models. Using a CCB cohort, our previously validated models have demonstrated good performance and outperformed the standard clinical criteria. Our study suggests that better risk counseling may be achieved by GCs using these already-developed mathematical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computation Biology, Houston, TX.
- Rice University, Department of Statistics, Houston, TX.
- The University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Genetics, Houston, TX.
- The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX.
ORCID-Profile: Angelica M Gutierrez, Banu K Arun, Wenyi Wang
Förderung
- NCI NIH HHS
Zitieren
APA
Nguyen, N. H., Dodd-Eaton, E. B., Corredor, J. L., Woodman-Ross, J., Green, S., Gutierrez, A. M., Arun, B. K., & Wang, W. (2024). Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01926
Vancouver
Nguyen NH, Dodd-Eaton EB, Corredor JL, Woodman-Ross J, Green S, Gutierrez AM, et al. Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01926
BibTeX
@article{Nguyen2024,
author = {Nguyen, Nam H and Dodd-Eaton, Elissa B and Corredor, Jessica L and Woodman-Ross, Jacynda and Green, Sierra and Gutierrez, Angelica M and Arun, Banu K and Wang, Wenyi},
title = {Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01926}
}
EUVIMED